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INTRODUCTION
Labour refers  to the onset  of  effective uterine contractions 
leading  to  progressive  effacement  and  dilatation  of  the  cervix 
resulting in the expulsion of the fetus, placenta and the membranes.
According to Alec  Turnbull (1976).  “The spontaneous onset 
of labour is a robust and effective to  mechanism which is preceded 
by the  maturation of  several  fetal  systems,  and should be  given 
every opportunity to operate on the own we should only induce 
labour when we are sure that we can do better.”
The ideal method of induction of labour would mimic 
exactly  the  onset  of  spontaneous  labour.  Not  surprisingly  no 
method of induction currently available does this.  
Induction is indicated when the benefits to either the mother 
or the fetus outweigh those of continuing the pregnancy.
The  American  college  of  Obstericians  and  Gynecologists 
(1999a) does not support elective induction, except for logistical 
reasons  such  as  risk  of  rapid  labour,  the  women  lives  a  long 
distance from the hospital or for psycosocial indications.
Induction of labour has two important components, cervical 
ripening  and  stimulation  of  uterine  contractions  to  achieve 
dilatation of cervix and delivery of the fetus   It is well recognized 
that the success of induction of labour, which ultimately aims at 
achieving  vaginal  delivery  depends  to  a  great  extent  on  the 
favourability of the cervix or its readiness to go into labour. Agents 
used  for  cervical  ripening  may  lead  in  the  establishment  of 
contractions to women with on unfavourable cervix. 
 Pharmacological  methods  like  Prostaglandins  (PGE1 + 
PGE2)  relaxin and mechanical methods like membrane stripping, 
transcervical  catheter,  Hygroscopic  cervical  dilators  etc  are 
available for preinduction cervical  ripening.
Mifepristone is a 19 nor – Steroid with a greater affinity for 
the  progesterone  receptor  and  thus  blocks  the  action  of 
progesterone  at  a  cellular  level.  As  a  fall  in  the  level  of 
progesterone considered one of the important events in the onset of 
spontaneous labour. It therefore seems likely that this drug may be 
useful on induction.
      A number of studies have looked at the efficacy of mifepristone 
on cervical ripening.   There is a reduction in the induction delivery 
interval when induction is performed after mifepristone and a trend 
to a reduction in the rate of ceasarean section (Wing et al 2000).
AIM OF THE STUDY
1. To evaluate the efficacy and safety of oral mifepristone on 
induction of labour.
2. To  evaluate  the  effect  of  this  drug  on  parturition  and 
neonatal outcome.
3.  To  critically  evaluate  the  effect  of  this  drug  on  primi 
gravida and multigravida.
REVIEW OF LITERATURE
INDUCTION OF LABOUR:-
It  is  defined  as  an  intervention  which  is  intended  to 
artificially initiate  uterine contractions resulting in the progressive 
effacement and dilatation of cervix. As part of the definition, it is 
assumed that  this process will  result  in the birth of the baby by 
vaginal route.
Induction of labour is one of the most commonly practiced 
interventions in modern obstetrics.
Rates of Labour Induction:-
COUNTRY RATE SOURCE
USA 
England & Wales
Canada
38%
18%
19%
MARTIN and associates 2003 
2001 b  RCOG
2000 Health Canada
HISTORY:-
The human race for centuries found reasons to interfere with 
pregnancy by trying to hasten its conclusion.  Often this consisted 
of attempts to procure the abortion of unwanted pregnancies, but 
other more positive motives arose from the desire to relieve the 
mother of a life threatening pregnancy or to achieve mechanically 
more  favourable  vaginal  delivery  of  a  smaller  premature  baby 
through  a  constricted  birth  canal.   Through  time,  as  a  better 
perception of fetal  and maternal  risks developed alongside more 
efficient methods of labour induction, the indications shifted more 
commonly  to  serve  the  interest  of  the  fetus  perceived  to  be  in 
jeopardy.
The  first  reliable  technique  to  be  used widely  in  obstetric 
practice was amniotomy-artificial rupture of membranes.  Although 
this procedure  had probably been employed much earlier  it  first 
entered  the  medical  literature  in  1756.  When  Thomas 
Denman(1733-1815)  of  middle  sex  hospital  of  London  wrote 
extrolling its virtues. As a result it became known within Europe as 
the ‘English method’.
Another mechanical method was devised in 1861 by Robert 
Barnes  (1817-1907)  of  London,  Using  a  hydrostatic  bag  placed 
through  the  cervix  and  filled  with  water  with  a  view to  labour 
induction.   A  similar  approach  was  later  taken  by  Camille 
champetier de Ribes (1848-1935) in Paris and by James Vorhees 
(1869-1929) in Newyork.
More than a century later modern obstetricians would follow 
the same principle using a foley catheter, but by now understanding 
that the modus operandi was the local release of prostaglandins.
Hind  water  rupture  with  Drew  Smythe  Catheter  was 
introduced in 1931, but what gains in safety in terms of forewater 
preservation with reduced risk of Amniotic fluid infection and cord 
prolapse.   It  loses  in  efficiency  when  compared  with  forewater 
rupture.
Sir Henry Dale (1815-1968) made the first observation that 
posterior  pituitary  caused  uterine  contractions.  Pitocin  was  first 
extracted from the posterior pituitary gland in 1906, and Blair– Bell 
described  its  application  in the pregnant uterus in 1909.
In  1910,  it  was  used for  augmentation  in  cases  of  uterine 
inertia,  but  maternal  deaths  from  shock  were  reported  after 
intramuscular injection of pitocin.  Its use for induction was first 
reported by Theobald in 1952.
Oxytocin is the first polypeptide hormone synthesised by Du. 
Vigneaud and  Coworkers, 1953.  ‘Physiological drip’ (or) dilute 
intravenous  infusion  was  introduced  by  Geoffrey  Theobald 
pharmacologically  sound  approach  of  oxytocin  titration  was 
introduced by Alec Turnball and Anne –Anderson (1960)
Prostaglandin  was  first  isolated  from  seminal  fluid  of 
monkeys,  Sheep and Goat,  by  ulf  von Euler   at  the  Koralinska 
institute  in  stockholm  in  1935.   Elias  corey  Synthesised 
dinoprostone  in  1970  at  the  Harvard  University  Bergstrom, 
Samuelson and vane jointly received the 1982 Nobel Prize for their 
discovery of prostaglandins.
RU -486 (or ) mifepristone:-
The Compound was discovered by Researchers  at  Roussel 
uclaf of France in 1980 while they were studying glucocorticoid 
receptor antagonists.  Etenne – Emile Baulieu recognized its anti 
progestrone  activities  and  saw  its  potential  for  the  induction  of 
medical abortion the dug was first licensed in France in 1988, for 
use  in  Combination  with  a  Prostaglandian,  under  the  name  of 
mifegyne.
Indications for Induction of Labour :
1. For  high  risk  pregnancies  where  there  is  risk  to  both  the 
mother and the fetus
Preclampsia and eclampsia
Hypertension complicating pregnancy
Renal disease complicating pregnancy
Premature rupture of membranes and chorioamnionitis
2. Where there is increased likely risk to mother, if termination 
is not advocated
1. Intrauterine death
2. Abruptio placenta
3. Wherer the fetus is at risk
1. Post term pregnancies
2. Chronic placental insufficiency
3. Rh isoimmunisation
4. Maternal diabetes complicating pregnancy
5. Previous unexplained still births
6. Intrauterine growth restriction
7. Anamalous baby
Contra indications :   Absolute contraindications :
1. When vaginal delivery is contraindicated
a) major degrees of cephalopelvic disproportion
b) previous VVF repair
c) pelvic tumour
d) carcinoma cervix
e) previous uterine surgery
f) active herpes
2.  Malpresentations cord prolapse or presentation
3.  Placental abnormalities like vasa previa and type III and type 
IV placenta previa
Relative contraindications :
1. Grand multipara
2. Maternal heart disease
3. Abnormal foetal heart rate pattern
PRE INDUCTION CERVICAL RIPENING:-
The condition of  the  cervix is important to the Success of 
labour Induction, Cervical scoring was first described  by Bishop in 
1964.  Various modifications of Bishops original score have been 
suggested and the  most  widely  used is  CALDER’S MODIFIED 
BISHOP’S SCIRE (1974).
Score 0 1 2 3
Dilatation (cm) < 1 1-2 2-4 >4
Effacement (cm) >4 2-4 1-2 >1
Station (cm) -3 -2 -1,0 +1,+2
Consistency Firm Average Soft
Position Posterior Mid-
Anterior
A  score  of  9  conveys  a  high  likelihood  for  a  successful 
induction.   For  research  purposes  a  Bishop  score  of  4  (or)  less 
identifies  as  unfavourable  cervix  and  may  be  an  indication  for 
cervical Ripening.
Cervical ripening is the process by which the cervix becomes 
soft, compliant & partially dilated.  It is a fundamental process that 
must occur, if parturition is to progress smoothly.
Cervical  ripening is  due to  a  combination of  Biochemical. 
Endocrine, mechanical and possibly inflammatory events.
It is believed that the increasing myometrial contractility, in 
the  form  of  Braxton  Hicks  contractions  seen  with  advancing 
gestation plays a vital role in the effacement of cervix, prior to the 
actual commencement of labour.
Structurally, the cervix is mainly composed of collagen, as 
opposed  to  the  myometrium,  which  predominantly  consists  of 
smooth muscle.   There  are  four types of  collagen in  the  human 
body – I, II, III, IV.
The cervix is predominantly composed of types I (66 percent) 
and III (33 percent).  The firmness of the cervix in the non-pregnant 
state is mainly due to the properties of these collagen fibrils.  These 
bundles in  turn are embedded in ground substance consisting of 
proteoglycans.
The  proteoglycans  are  made  of  a  central  core  of  proteins. 
which  are  linked  to  glycosaminoglycans,  which  are  repeating 
disaccharide  units  composed  of  a  hexosamine  (glucosamine  (or) 
galactosamine)  and  an  uronic  acid  (glucuronic  acid  or  iduronic 
acid) residue.
In  the  cervix,  the  main  glycosaminoglycans  are  dermatan 
sulphate  and  chondroitin  sulphate,  both  of  which  are  highly 
negatively charged and hydrophobic.  Hence, they repel water and 
are  responsible  for  the  firmness  of  the  cervix.   Moreover,  by 
interacting  with  the  central  protein  core  as  well  as  among 
themselves, glycosaminoglycans facilitate the optimum orientation 
of the collagen fibrils, enhancing, the mechanical strength of the 
cervix.
Towards  term,  the  glycosaminoglycan Concentration  alters 
and  the  dermatan  and  chondroitin  sulphate  are  replaced   by 
hyaluronic acid, which has different physio chemical properties.
Hyaluronic  acid  is  hydrophilic  and  imbibes  water 
Accumulation  of  water  within  the  substance  of  the  cervix 
destabilises the collagen fibrils, contributing to cervical ripening.
The  water  content  of  the  human cervix  increases  from 80 
percent in the non- pregnant state, to 86 percent in late pregnancy 
(Liggins 1978; Uldbjerg et al 1983a).  The accumulation of water 
in between the collagen fibrils has a scattering or dispersing effect, 
resulting in reduced mechanical strength.  
Collagenase & leukocyte elastase levels are found to increase 
with  advancing  gestation  and  are  associated  with  progressive 
decline in the concentration of cervical collagen.  (Uldbjerg et al 
1983 b).
The  mature  collagen,  which  has  many  crosslinks  that  are 
responsible  for  its  tensile  strength,  is  replaced  by  an  immature 
collagen which has a few cross links.
Ganstrom  et  al  (1991)  have  shown  that  the  insufficient 
remodelling of collagen during  pregnancy is an independent factor 
that results in labour.
METHODS OF CERVICAL RIPENING:-
There  has  often  been  an  attempt  to  make  a  distinction 
between women who are undergoing cervical ripening and women 
who are being formally induced.  This tendency is artificial, as in 
all the intention is to artificially stimulate the onset of labour.
Women  undergoing  cervical  ripening  are  simply  those  in 
whom there  is  an  unfavourable  cervix  and where  the  indication 
allows the greater time expected for induction to establish active 
labour.
As the first stage of labour is a seamless progression from the 
latent into active phase, so induction is a progression from cervical 
ripening through to the onset of  contractions.
Agents  used  for  cervical  ripening  may  lead  to  the 
establishment  of  contractions  in  women  with  an  unfavourable 
cervix. Many agents can be used in both women with high and low 
cervical scores, albeit with a different expectation of the time likely 
before delivery will be achieved.
Non-Pharmacological methods:-
Sexual  intercourse,  herbal  remedies,  castor  oil,  enemas, 
acupuncture,  baths.   No Study has shown any proven benefit  of 
these therapies for induction of labour.
Sweeping of membranes:-
It is an old method of inducing labour described by Hamilton 
in 1810.
Mc Colgin and Collegues (1990) reported that two thirds of 
women who underwent stripping entered spontaneous labour within 
72 hours.
The procedure of membrane sweeping causes an increase in 
the levels of Prostoglandin F2 alpha (Mc colgin et al 1993).
Bouvelian and colleagues (1999) – Sweeping the membranes 
as a  routine at term reduced the chances of pregnancy progressing 
beyond 41 weeks and reduce the need for induction of Labour from 
36 to 21%.
Mechanical methods:-
Intrauterine  Extraamniotic   Foley  Catheter  with  bulbi 
inflation to 30ml  -   Rapid improvement in Bishop Scores  and 
shorter labours (Sherman and Colleagues 1996).
Bujold and coworkers (2004) reported a lower incidence of 
success when induction by Foley catheter was compared with that 
by oxytocin – 56 versus 78 percent.
Extra – amniotic saline infusion (EASI):-
Abromovici and coworkers (1999) reported that 85 percent of 
those induced by catheter infusion delivered within 24hrs compared 
with 55 percent of those given misoprostol.
Mullin and associates (2002) reported that mean induction to 
delivery interval was shorter in the catheter plus oxytocin group.
Hygroscopic cervical dilators:-
Guinn and co-workers (2000) reported a longer induction to 
delivery interval with cervical dilators plus oxytocin compared with 
that of EASI  Plus oxytocin.
The use of hygroscopic dilators appear to be safe, although 
anaphylaxis has followed laminaria insertion (Cole and Neek 2000) 
The  attraction  of  dilators  is  their  low  cost  and  ease  of 
placement and removal.
As mechanical methods are believed to facilitate ripening by 
causing local release of Prostaglandin their use has been superseded 
by administration of local prostaglandin in most units.
Pharmacological methods:-
Prostaglandins:-
Prostaglandins  probably  induce  cervical  ripening  by 
producing  vasodilatation  of  the  cervical  blood  vessels  and 
increased extravasation of the neutrophil (Rajabi et al 1988).
The  extravasated  neutrophils  then  degranulate  and  release 
large  quantities  of  collagenases  and  proteases  which  degrade 
cervical collagen and soften the structure of the cervix (Rajabl et al 
1988).
Prostaglandins act synergistically with interleukin 8 (IL -8) to 
stimulate the fibroblasts to produce hyaluronic acid (Ogavia et al 
1998)  which  in  turn  alters  the  composition  and structure  of  the 
cervix.
This  effect  on  the  cervix  along  with  uterotonic  effects  of 
prostaglandins  and  other  uterotonics  on  the  uterus  enables  the 
cervix to efface and dilate during labour to allow parturition.
Prostaglandin E2
Compared  to  the  placebo,  the  induction  of  labour  with  a 
vaginal prostaglandin gel has been consistently shown in several 
trials  to  be  associated  with  and  increased  Bishop  score  and  a 
reduced  incidence  of  ceasarean  section  (Brennand  and  Green 
1998).
The  United  Kingdom’s  national  institute  for  clinical 
Excellence  (NICE)  Guidelines  on  the  induction  of  labour 
recommends that prostaglandin E2 should be used in preference to 
oxytocin  for  the  induction  of  labour  in  women  with  intact 
membrane regardless of their parity or the ripeness of the cervix.
In  women  with  term  prelabour  rupture  of  membranes 
Prostaglandin  (dinoprostone  PGE2)  and  oxytocin  are  equally 
effective for the induction of labour, regardless of their parity (or) 
the state of the cervix (Tan and Hannah 2000).
Prostaglandin E1:- 
1. Misoprostol use may decrease the need for oxytocin achieve 
higher  rates  of  vaginal  delivery  within  24hrs  of  induction  and 
reduce  induction  –  delivery  intervals.   (Sanchex  –  Ramos  and 
colleagues, 1997).
2. The  committee  on  obstetrics  and  gynecologists  (1999  b) 
recommended the use of a 25ug intravaginal dose.
3. Data  from  the  United  Kingdom  Cochrane  centre  support 
these  recommendations.  But  the  investigators  cautioned  that 
increased  uterine  hyperstimulation  with  adverse  fetal  heart  rate 
changes was of concern (Hotmeyr and associates, 1999).
4. IN DECEMBER 2000, the American college of obstetricians 
and Gynecologists  reaffirmed its  recommendation for  use  of  the 
drug because of proven safety and efficacy.
5. A 25 microgram dose was found comparable to dinoprostone 
gel (Van Gemund and associates, 2004).
OXYTOCIN:-
In  modern  obstetric  practice  oxytocin  is  more  commonly 
used in combination with amniotomy making it unsuitable  for use 
in women who have cervical scores below 6.
When compared to  induction  with prostaglandins  evidence 
suggests that oxytocin induction is associated with a lower chance 
of delivery within 24hours.
In  women  with  an  unfavourable  cervix,  induction  with 
oxytocin was associated with higher rates of ceasarean section.
Lower dose regimens are recommended with starting doses 
of 1-2 milli units / min, increased at intervals of not less than 30 
minutes.  The maximum dose is the minimum needed to maintain a 
contraction  frequency  of  3-4  in  ten  minutes  (or)  an  absolute 
maximum of 32 milli units per minute.
RELAXIN:-
Relaxin has been used both vaginally and intracervically to 
induce labour but studies have failed to show any benefit compared 
to prostaglandin  (Kelly 2002b).
Hyaluronidase  and  estrogen  are  of  historical  interest  only 
(Thomas et al 2001).
RU 986 OR MIFEPRISIONE:-
It is a derivative of 19 nor progestin norethindrone containing 
a  dimethyl  –  aminophenol  substituent  at  the  11  beta  position  it 
effectively  competes  with  both  progesterone  and glucocorticoids 
for binding to their respective receptors.
This  antiprogestin  has  been  studied  extensively  for 
preinduction cervical ripening at term.
a. A  200mg  dose  given  orally  for  2  days,  48hrs  before  the 
formal  induction  Engdman  and  associates  (1992)  reported 
that  mifepristone  is  a  safe  efficient  and  suitable  induction 
agent for initiation  of labour at term.
b. Single dose of  400mg mifepristone was effective for cervical 
ripening  and  reduce  the  induction  delivery  interval 
( Giacalone PL: Targosz V : Laffargue : Boog G: faure JM) 
c. Induction of labour is facilitated in term women with prior 
ceasarean section by the use of mifepristone.  This induction 
agent appears safe and useful with no adverse effect on the 
fetus or mother (Lelaider c: Barton C: Benifla JL, Fernandaz 
H : Bourget P: Frydman R:  (1994).
d. Single dose of 400 milligram mifepristone (for Preinduction 
cervical  ripening  in  women  with  an  unripe  cervix.)   is  a 
simple  and  effective  treatment  (  Stenlund  PN:  Erkman  G: 
Aedo AR: Bygdeman N 1999).
e. Mifepristone had a modest effect on cervical ripening when 
given 24hrs before labour induction, appearing to reduce the 
need for  misoprostol  and oxytocin  compared with  placebo 
(Wing Da: Fassect Mj: Mishell DR 2000).
Amniotomy:- 
Artificial rupture of membranes can be used to induce labour: 
but implies a commitment to delivery. The main disadvantage of 
amniotomy  when  used  for  induction  is  the  unpredictable  and 
occasionally long interval, to the onset of contractions.
There  is  an  increased  incidence  of  chorioamninitis  (23 
percent)  and cord  compression patterns  (12 percents)  with  early 
amniotomy.
RISKS OF INDUCTION OF LABOUR:-
Increase in ceasaren Section rate:  
The risk of  ceasarean section increased nearly threefold in 
primigravid women (11.8% Vs 27.9%) and doubled in multigravid 
women  (3.4%  Vs  8.5%)  who  were  induced  compared  to  those 
labouring spontaneously (RCOG 200 lb).
Uterine Hyper Contractility:-
Uterine hypertonus is defined as a single uterine contraction 
that lasted 2 or more minutes. 
Tachysystole  is  defined  as  at  least  12  contractions  in  20 
minutes.  Hyperstimulation  is  defined  as  either  hypertonus  (or) 
tachysystole associated with abnormal FHR pattern.  
Misoprostol was associated with significantly increased risk 
of tachysystole or hyper stimulation when compared with PGE 2 
gel (WING and Coworkers 1995a, 1995b).
Induced  labour  is  associated  with  on  increased  risk  of 
postpartum hemorrhage.
Prolonged induction is associated with a small increase in the 
risk of infectious morbidity with an estimated 10% incidence noted 
after 40hrs of induction (Bahn et al 1998).
Oxytocin induction has been reported to increase the risk of 
neonatal Hyperbilirubinemia.
Iatrogenic prematurity occurs inadvertently and a review of 
the gestational age prior to induction is essential.
Failed induction: 
Defined by Duff et al (1984), as the failure to enter to active 
phase of labour, after twelve hours of regular uterine contractions. 
Failed induction, is diagnosed when, a patient who was induced, 
does  not  deliver  vaginally  in  the  absence  of  fetal  distress,  with 
acute events like abruption or cord prolapse, and failure to progress 
due to malposition and or if the patient has not entered the active 
phase  of  labour  despite  adequate  management  for  twelve  hours 
(Arulkumaran et al 1985).
MIFEPRISTONE
INTRODUCTION:-
Mifepristone  was  originally  designed  by  the  French 
pharmaceutical company (Romainville, France) as a glucocorticoid 
antagonist  and  was  only  serendipitously  found  to  have 
antiprogesterone effects.  Many of its potential  actions still  under 
research.
Pharmacodynamics:-
Mifepristone  is  a  19  nor-steroid  with  potent  competitive 
antiprogestational  and  significant  antiglucocorticoid  and  anti 
androgenic activity.
At the molecular level, the most important features are high 
binding  affinity  to  the  receptor,  interaction  of  the 
phenylaminodimethyl group in the 11 beta position with a specific 
region  of  receptor  pocket  and  mifepristone  induced 
transconformation differences in the ligand binding domain.    It 
renders the mifepristone – progesterone receptor complex inactive 
and unable to promote transcription of cellular DNA.
Mifepristone binds with very high affinity (2-10 times that of 
progesterone)  to  the  progesterone  receptors.   In  the  absence  of 
progesterone, however, mifepristone can act as a partial agonist.
Endometrial Effects:-
Mifepristone blocks the effects of natural Progesterone on the 
endometrium  and  decidua.   This  leads  to  degeneration  and 
shedding of the endometrial lining thereby preventing or disrupting 
implantation of the conceptus.
Mifepristone  also  increases  both  uterine  production  of 
Prostaglandins and uterine sensitivity to the contractile effects of 
prostaglandins.
Mifepristone acts directly on the uterine muscle through an 
entirely separate mechanism, perhaps by increasing gap junctions 
in the myometrium.
Tissue culture studies have shown that mifepristone continues 
to display procontractile effects on the uterus even when the effects 
of Prostaglandins are neutralised by treatment with indomethacin.
CERVIX:  Mifepristone stimulates the release of nitric oxide and 
the expression of cervical iNos in cervical cells of women in early 
pregnancy (Human reproduction 2006 21(8); 2180-2184).
Mifepristone  induced  a  decrease  in  the  cervical  tensile 
strength  that  was  associated  with  a  decrease  in  the  collagen 
organization.   Mifepristone led to  collagen fragmentation with a 
significant  decrease in  fibril  length and diameter,  although fibril 
bundling  remained  unaffected.  Matrix  metalloproteinase-2 
expression  increased  after  the  administration  of  mifepristone. 
(American Journal of obstetrics and gynecology, volume 194, Issue 
5, Pages 1391-1398).
Gonodotropic effects:-
The effects of mifepristone on the Hypophysical – ovarian 
axis  have  also  been  studied  and  reported  in  the  literature. 
Mifepristone  has  differing  effects  on  the  usual  hormonal  milieu 
when it is administered during the menstrual cycle.
Given  during  the  follicular  phase,  its  antiprogestin  action 
results  in  attenuation  of  midcycle  LH  Surge  from  pituitary 
-slowing  of  follicular  development  and  delay  or  failure  of 
ovulation.
Adrenocortical effects:-
Mifepristone  has  antiglucocorticoid  effects  by  binding  to 
glucocorticoid receptors with on affinity that is 2-3 times that of 
Dexamethasone.  It interferes with cortisol binding to tissues in the 
hypothalamus.  This blocks normal negative feedback mechanisms 
and causes a compensatory increase in serum levels of both cortisol 
and corticotropin.
Mifepristone binds to cortisol receptors in the periphery and 
therefore blocks the effects of circulating cortisol in target tissues. 
Higher  doses  of  mifepristone  are  needed  to  produce  this 
antiglucocorticoid  effect  as  opposed  to  an  antiprogestin  effect 
because blockade in the periphery is opposed by increased cortisol 
and corticotropin secretion.
No  Reports  of  clinically  significant  relative  cortisol 
deficiency  have  been  reported  when  it  has  been  used  as  an 
antiprogestin, even with long term use of mifepristone for several 
weeks.
Mifepristone  has  almost  no  affinity  for  estrogen  and 
mineralocorticoid receptors.
Pharmacokinetics:-
Mifepristone  has  a  bioavailability  of  70%  after  oral 
administration, peak plasma concentrations are reached in 1-2 hrs 
after a single oral dose.  It has a half life of approximately 20-30 
hours
The pharmacokinetics of mifepristone are non-linear.   Serum 
drug  concentrations  increase  progressively  after  oral  doses  from 
50-  100mg,  but  no  further  increases  occur  after  doses  of  100-
200mg.  This is partly due to progressive saturation of Alpha-1 acid 
glycoprotein,  the serum binding  protein for mifepristone.
The unbound mifepristone is quickly metabolized in the liver 
by  a  two  step  process,  demethylation  and  hydroxylation,  with 
metabolites  detectable  in  plasma about  1  hr  after  oral  ingestion. 
The  concentration  of  metabolites  increases  in  a  dose  dependent 
manner. Metabolites bind to progesterone receptors with an affinity 
of  10-20%  that  of  the  parent  compound.   These  metabolites 
probably  contribute  little  to  the  pharmacologic  effect  of 
mifepristone.
Both mifepristone and its metabolites are excreted primarily 
in the feces via the biliary system.  Little is cleared by kidneys. 
Mifepristone crosses the placenta.   The maternal  – fetal  ratio in 
plasma is approximately 9:1.
Clinical Uses:-
1. First Trimester abortion:-
Mifepristone softens and dilates the cervix, causes decidual 
necrosis,  increases  prostaglandin  release,  increases  uterine 
contractions  and  enhances  uterine  sensitivity  to  administered 
prostaglandins.
FDA approved 
protocol
Other evidence based 
regimens
Mifepristone dosage 600mg (Day1) 200mg (DAY1)
Misoprostol dosage 400mg PO 400mg PO (or) 800mg PV
Gestational limit <49 days <63 days
Location of misoprostal 
administration 
At clinic At clinic / home
Timing  of  misoprostol 
administration 
DAY 3 DAY 2,3,(or)4
Timing of initial 
follow up 
DAY 14 DAY 4-14
No  of  clinical  visits 
required 
3(or)more >2
67% of women will have a complete abortion within 4 hrs of 
using misoprostol, 9 of will have complete abortion within 24hrs of 
using misoprostol.
Preoperative cervical preparation before vaccum aspiration:-
200mg  mifepristone  administrated,  36  hrs  before  vaccum 
aspiration  is  a  highly  effective  cervical  priming  agent.   (BJOG 
Volume 98 issue to pages 1025-1030).
Induction of second trimester abortion:-
Mifepristone  with  prostaglandins  either  misoprostol  (or) 
germprost is  a safe and effective method which reduces induction 
–abortion interval (BJOG Volume 100: issue 8, page 758-761) 
Intra uterine demise (21weeks to 40weeks):- 
Wagarrachi et al (2002) – mifepristone 200mg following by 
200mg misoprostol if gestational age is less than 34 weeks, First 
dose of misoprotol was given 36 hrs after oral mifepristone, and 
then repeated every 4th  hourly orally upto four doses.
There were no adverse maternal events and this regimen is 
safe and effective.
Mifepristone  is  a  safe  and  efficient  induction  agent  for 
initiation of labour in women at term (Frydmen et al 1992).
Emergency contraception:-
10mg  mifepristone  administered  within  5  days  of  sexual 
intercourse is an effective contraceptive with an acceptable profile 
of side effects.  
Fibroid :
Progestrone binds either PR-A / PR-B,  mifepristone exerts 
its effects mainly through PR-A which is found in lieomyomas in 
greater  amounts  than  PRB,  mifepristone  decrease  lieomyoma 
volume by approximately half. (Eisinger 2003).
Endometriesis:-
50mg mifepristone daily for 3 months causes 55% regression 
of endemetriotic implants.
Neuropsychiatric disordess:-  
Mifepristone  is  a  potent  glucocorticoid  and  progesterone 
receptor  antagonist.   The  pathophysiology  of  number  of 
neuropsychiatic  disorders  implicates  abnormalities  in 
glucocorticoid  function.   These  include  mood  disorder  such  as 
psychiatric major depression, and bipolar depression.  In addition 
cognitive disorders such as Alzheimer’s disease might also partially 
mediated by abnormalities in the HPO axis.  Preliminary studies 
suggest  that  mifepristone  might  have  a  role  in  the  treatment  of 
number of  neuro psychiatric  disorders  (Trends  in  Endocrinology 
and metabolism volume 17, issue 10, Dec.2006).
Unresectable meningioma:-
As  progesterone  receptors  are  expressed  in  meningiomas, 
partial  response  or  prolonged  stabilisation  was  seen  in  47% 
following T.mifepristone 200mg daily for 6-12 months.
(PEREZ  and  BRADY’S  Principles  of  radiation  oncology,  Page 
744).
Breast cancer:-
Mifepristone effectively reversed P-glycoprotein and MDR-
associated  protein  in  mice  thymoma  cells,  mifepristone  induces 
growth  arrest  and  active  cell  death  of  the  antiestrogen  resistant 
breast cancer cells.
The  combination  of  antiestrogen and antiprogestin  reduces 
the  emergence  of  antiestrogen  resistant  breast  cancer  cells  and 
ultimately improve the therapeutic index of antiestrogen therapy.
Cushing Syndrome:-
Larger doses of mifepristone 5 to 22 mg/kg must be used to 
obtain antiglucocorticoid effect.
Prostate Cancer:-
Mifepristone is an effective inducer of apoptosis and useful in 
androgen independent prostate carcinoma.
HIV:-
Mifepristone has antiretroviral  effect  by  inhibiting the  Vpr 
induced  transactivation  of  the  HIV–LTR  in  dose  dependent 
manner.
IVF:- 
Mifepristone is effective for the prevention of Premature LH 
surge in women undergoing controlled ovarian hyperstimulation for 
IVF,  however  endometrial  receptivity  status  requires  further 
evaluation before this drug can be considered as a new alternative 
to GNRH agonist (or) antagonist.  
Contraindications:-
(I) Hemorrhagic disorders (or) concurrent anticoagulant therapy.
(II) Inherited Porphyrias
(III) Chronic adrenal failure
(IV)History of allergy to mifepristone
(V) Concurrent  long  term  corticosteroid  therapy  (or)  recent 
therapy with corticosteroid.
(VI)  Chronic medical disorders.
(VII) Age more than 35years 
(VIII)  Smokers (>10 cigarettes /day).
Drug  interactions:
On  the  basis  of  this  drug  metabolism  by  CYP  3A4, 
Ketoconazole, itraconazole, erythromycin and grape fruit juice may 
inhibit  its  metabolism.   Rifampin,  dexamethasone  and  certain 
anticonvulsants like phenytoin, phenobarbitone and carbamazepine 
may induce mifepristone metabolism.
Side effects;-
Adverse  Reactions  associated  with  single  dose  of 
mifepristone are  nausea,  vomiting,  diarrhea,  dizziness,  headache, 
fever, warmth and chills.
Long  term  administration  of  mifepristone  may  cause 
anovulatary amenorrhea, hot flushes, transient thinning of hair and 
weigh loss.
MATERIAL AND METHODS
This  prospective  clinical  trial  was  carried  out  in  the 
Department  of  obstetrics  and  gynaecology,   Government  Rajaji 
Hospital  Madurai,  during the  period of  May 2009 to November 
2009.
The  purpose  of  the  study  was  to  evaluate  the  safety  and 
efficacy  of  mifepristone  as  an  orally  active  inducing  agent  in 
women with unfavourable cervix at term (Bishop score < 4).
Inclusion Criteria :
i) Singleton live pregnancy in cephalic presentation.
ii) Gestational age more than 38 weeks
iii) Bishop score < 4
iv) Reactive FHR pattern
v) Intact membranes
vi) Maternal age > 18 years and < 35 years
vii) Term and post term pregnancies with no contraindications 
for vaginal delivery.
viii) No  contraindications  for  mifepristone  and  prostaglandin 
E2gel
ix) Primi gravida and second gravida
Exclusion Criteria :
i) Multiple pregnancy
ii) Malpresentations
iii) Cephalopelvic disproportion.
iv) Premature rupture of membranes
v) Bishop score > 4
vi) Non reactive FHR pattern
vii) Maternal age < 18 years and > 35 years
viii) Previous H/o ceasarean section or uterine surgery
ix) Contraindications for vaginal delivery
x) Contraindications for mifepristone and prostaglandin
xi) Chronic medical disorders
xii) Parity  > 2.
This  study  contained  50  women  who  were  inpatients  in  the 
labour and delivery units of Government Rajaji Hospital, Madurai.
On admission, a detailed history was taken.  Complete general 
and  obstetric  examination  was  carried  out.  Under  strict  aseptic 
precautions,  vaginal  examination  was  done.  Bishop’s  score  was 
assessed.
Gestatational  age  was  determined  by  the  date  of  the  last 
menstrual  period  preceded  by  regular  cycles  and  confirmed  by 
ultrasonography no later than 20 weeks.
Routine obstetric scan for fetal maturity and well being was 
done.  Once the inclusion criteria were fulfilled,  the patient was 
counselled and written informed consent obtained.
Treatment Schedule :
On Day 1, after assigning the initial Bishop’s score, 200 mg 
of T. mifepristone was given orally.  After 24hrs, Bishop’s scores 
were reassessed. If Bishop’s scores were less than 6 and reactive 
FHR pattern, second dose of mifepristone 200 mg orally was given 
on  Day  2.   If  Bishop  scores  were  more  than  6,  labour  was 
augmented with oxytocin.
After 48 hrs of initial treatment, if Bishop’s scores were less 
than 6 and reactive FHR pattern induction with PGE2 gel was done 
on  4th day.   If  Bishop’s  scores  were  more  than  6,  labour  was 
augmented  with  oxytocin.  Once  in  active  labour,  patients  were 
managed routinely.
Monitoring of the patients :
From the start of induction with mifepristone, uterine activity 
and  fetal  heart  rate  were  monitored  clinically.   Frequency  and 
duration of contractions were monitored by abdominal palpation. 
Fetal heart rate was monitored by using Pinard’s fetoscope, once in 
every 30 minutes till the onset of labour pains, once in 15 minutes 
during the first stage, once in 5 minutes during the second stage. 
The pulse rate, blood pressure and temperature were recorded every 
hour.  Progress was monitored by using WHO partogram during 
active stage. If the membranes were ruptured, vaginal examination 
was done to assess  the Bishop’s score and colour of liquor was 
noted.  If any maternal side effects like nausea, vomiting, fever, 
chills etc were noted.  If any FHR abnormality was present, it also 
noted
The outcome was assessed by
i) Induction – delivery interval
ii) Duration of 1st and 2nd stage
iii) Intrapartum  complications  like  uterine  contractility 
abnormalities,  meconium  passage,  abnormal  FHR 
pattern
iv) Mode of delivery
v) Neonatal outcome Apgar 1 minute & 5 minutes, NICU 
admission)
vi) Need for oxytocin
vii) Need for prostaglandin E2 gel
viii) Maternal side effects
Success of Induction was assessed by
i) Patient who delivered vaginally within 48 hrs of the start 
of induction.    or
ii) Bishop’s score of more than 6 at the end of 48 hrs.
Failure of Induction :
i) Bishop’s score of 6 or less than 6 at the end of 48 hrs.  or
ii) Patient who underwent caesarean section
Statistical Tools :
The  information  collected  regarding  all  the  selected  cases 
were recorded in a master chart.  Data analysis was done with the 
help of computer using Epidemiological information package. (EPI 
2008).
Using this software frequencies, percentages, means, standard 
deviations,  Chi-square  test  was  used  to  test  the  significance  of 
difference  between  quantitative  variables  and  Yate’s  test  for 
qualitative variables.  A ‘p’ value less than 0.05 is taken to denote 
significant relationship.
RESULTS
Table 1
Age in 
years
Primi (no=30) Multi (no=20) Total Total
No. % No. % No. %
<20 3 10 3 15 6 12
21-25 22 73.3 11 55 33 66
26-30 5 16.7 6 30 11 22
>30 - - - - - -
Total 30 100 20 100 50 100
Mean age 
S.D/
23.4
2.3
24.0
2.4
23.7
2.3
P 0.3631    (Not significant)
Among  the  30  primigranda  selected,  22  (73.3%)  were 
between 21-25 years of age, 5(16.7%) were between 26-30 years, 
and  3  (10%)  were  between  18-20yrs.  None  were  more  than 
30years.
Among the 26 multigravida selected, 11(55%) were between 
21-25 years, 6 (30%) were between 26-30 and 3(15%) between 18-
20 years.  None were more than 30 years.
TABLE 2
GRAVIDITY
GRAVIDITY No. %
PRIMI 30 60%
MULTI 20 40%
TOTAL 50 100
Among the 50 patients selected 30 (60%) were primigravida 
and 20 (40%) were multigravida.
TABLE 3
INDICATION FOR INDUCTION
S.No INDICATION PRIMI 
( No= 30)
MULTI 
(NO=20)
TOTAL 
No.
TOTAL 
%
No. % No. % No. %
1 Postdatism 27 90 18 90 45 90%
2 Pre eclampsia 3 10 2 10 5 10%
Total 30 100 20 100 50 100
The major indication for induction was for postdatism which 
accounted for 90% (45) of the study group.  The next indication 
was for pre eclampsia accounted for 10% (5) of the study group 
(Both in Multi & primigravida).
TABLE 4
BISHOP’S SCORE AT THE START OF THE STUDY
SCORE PRIMI MULTI TOTAL 
No.
TOTAL 
%
No. % No. % No. %
0 5 16.7 - - 5 10
1 2 6.7 3 15 5 10
2 19 63.3 13 65 32 64
3 4 13.3 4 20 8 16
TOTAL 30 100 20 100 50 100
Mean Score 
S.D
1.73                 2.05               1.86
0.91                  0.6                 0.81
‘P’   0.303   (Not Significant)
5 Primi and none of the multi that is a total of 10% had a 
bishop’s score of 0.  2 primi and 3 multi that is a total of  10% had 
a score of ‘1’  while 19 Primi and 13 multi that is a total of 64% 
had a score of ‘2’ while 4 primi and 4 multi that is a total of  16% 
had a score of 3 at the beginning of the study.
Of the 30 primigravida, 26 (36.7%) had a Bishop’s Score of 
<2 while 4 (13.3%) had a bishop’s score of ‘3’
Of the 20 multigravida ,16 (80%) had a Bishop’s score of < 2 
while 4(20%) had a score of ‘3’ 
TABLE  5
Number of Doses (mifepristone) Required
No of Doses PRIMI         MULTI TOTAL TOTAL
No. % No. % No. %
Single close 
on DAY 1
21 70 19 95 40 20
Two dose on 
DAY 1 & 2
9 30 1 5 10 20
Mean doses 1.3
0.47
1.05
0.22
1.2
0.4S.D
‘p’ 0.0321( significant)
A total of (80%) that is 21 Primi and 19 multi (95%) required 
single dose.  While (10%) 9 Primi and 1 (15%) that is a total of 
20% required two doses (30%).
Of the 30 primigravida, 21 (10%) required single dose and 9 
(30%) required two doses.
Of the 20 multigravida 19 (95%) required single dose 
and 1 (5%) required two dose.
There was statistically significant difference in the no. of 
doses (mifepristone) required for Induction between primi gravida 
and multigravida (p=0.0321)
TABLE - 6
OXYTOCIN FOR AUGMENTATION
OXYTOCIN PRIMI        MULTI TOTAL TOTAL
No. % No. % No. %
REQUIRED IN 5 16.7 - - 5 10%
NOT REQUIRED 25 83.3 20 100 45 90%
‘P’ 0.0723  (Not significant)
Of  the  30  primigravida,  5  (16.7%)  required  oxytocin  for 
augmentation but none of the multigravida required oxytocin for 
augmentation,  that  is  a  total  of  10%  required  oxytocin  for 
augmentation.
However, there was no statistically significant difference in 
the  requirement  of  oxytocin  between  primigravida  and 
multigravida.
TABLE 7
PGE2 GEL FOR INDUCTION ON DAY 4
PGE2 GEL PRIMI         MULTI TOTAL TOTAL
No. % No. % No. %
REQUIRED IN 2 6.6 - - 2 4
NOT REQUIRED 28 93.4 20 100 48 96
‘P’ 0.3551  (Not significant)
Two primigravida (6.6%) and none of the multigravida, that 
is a total of 4% required PGE2 gel for induction on DAY 4.
TABLE 8
DURATION OF THE 1ST STAGE OF LABOUR
TIME          
( HOURS)
PRIMI         MULTI TOTAL TOTAL
No. % No. % No. %
<6 1 8.4 4 20 5 10.2
6-8 6 20.7 11 55 17 34.7
8-10 9 31 4 20 18 26.5
10-12 7 24.1 1 5 8 16.3
12-14 8 10.8 - - 3 6.1
14-16 3 10.3 - - 3 6.1
TOTAL 29 100 20 100 49 100
Mean duration 9.79
3.71
6.98
1.61
8.64
2.7
‘p’ 0.0001  Significant
1 of the 30 primigravida, was excluded, while calculating the 
first stage duration, as she was taken up for LSCS for fetal distress.
A total of 10.2%, that is 1 primi 4 multigravida, had a first 
stage  duration  of  less  than  6  hours.   A  total  of  87.8%  that  is 
23(79.2%) primi and 20 multi (100%) had a first stage duration of 
less than 12hrs. Only 6 Primi (20.2%) and none of the multi (0%) 
that is a total of 12.2% had first stage duration more than 12 hours. 
The mean first stage duration was 8.64 hours.
Therefore  first  stage duration less  than 12hrs was more in 
multigravida than in primigravida (100% vs 19.2%) 
The mean duration of first stage of labour for primi gravida 
was 9.79hrs and for multigravida was 6.98 hours 
The  mean  duration  of  first  stage  was  less  in  multigravida 
which was statistically significant (p=0.0001).
TABLE 9
DURATION OF THE 2nd  STAGE OF LABOUR
TIME          
( HOURS)
PRIMI         MULTI TOTAL 
No.
TOTAL 
%
No. % No. % No. %
0 – 10 5 17.2 7 35 12 24.5
10 – 20 16 55.2 12 60 28 57.1
20 – 30 7 24.1 1 5 8 16.4
>30 1 3.5 0 0 1 2.0
Total 29 100 20 100 49 100
Mean Duration
S.D.
16.06
7.29
10.78
2.78
18.91
6.34
‘p’ 0.0009 significant
1 of the 30 primigravida was excluded while calculating the 
second  stage  duration  as  she  was  taken  up  for  LSCS  for  fetal 
distress.
The majority of the patients, that is 98% which consisted 28 
(96.5%)  primi  and  20  (100%)  multigravida  had  second  stage 
duration of less than 30 minutes. Only 1 (3.5%) primigravida and 
none of the multigravida that  is  a  total  of  2% had second stage 
duration of more than 30 minutes.  The mean second stage duration 
was 13.9 minutes.
The mean second stage duration in primi was 16.06 minutes 
and  in  multi  gravida  was  10.78  minutes.   Therefore,  the  mean 
second  stage  duration  was  less  in  multigravida  than  the 
primigravida. (p=0.0009 - statistically significant). 
TABLE 10
(INDUCTION  - DELIVERY INTERVAL)
Time of 
Hours
PRIMI MULTI TOTAL TOTAL
No % No % No %
<8 - - 3 15 3 6.38
8-12 - - 12 60 12 25.53
12-16 9 35.33 3 15 12 25.53
16-20 4 19.81 1 5 5 10.63
20-24 3 11.11 - - 3 6.38
24-28 4 14.81 - - 4 8.5
28-32 1 3.70 - - 1 2.12
32-36 2 7.4 1 5 3 6.38
36-40 1 3.70 - - 1 2.12
>40 3 11.11 - - 3 6.38
TOTAL 27 100 20 100 47 100
Mean duration
S.D. 
23.11
11.9
11.48
5.41
18.41
11.41
‘p’ 0.0001        (significant)
Of  the  30  primigravida,  3  cases  were  excluded  while 
calculating induction – delivery interval.  Among the three one was 
taken up for LSCS for fetal  distress,  the remaining two required 
PGE2 gel  induction  on  day  4  as  their  bishop  Score’s  remained 
unfavourable 
A total of 74.45%  that is 16 (59.25%) primi and 19(95% ) 
multigravida  delivered  within  24hrs.   A  total  of  17.01% that  is 
1(25.9%) primi and 1(5%) multi delivered within 36 hrs. Only 4 
(14.7%) primi but none of the multigravida, that is a total of 9.5% 
delivered   after  36  hrs  of  induction,  mean  induction  delivery 
interval was 18.61 hrs.
The mean induction delivery interval in primi was 23.7 hours 
and in multigravida was 11.48 hrs. Therefore the induction delivery 
interval  was  shorter  in  multigravida  (p=0.001–  statistically 
significant.)
TABLE - 11
INTRAPARTUM COMPLICATIONS
Intrapartum
Complications
PRIMI MULTI TOTAL TOTAL
No % No % No %
Uterine
Contraction 
Abnormalities
Hypertonus 0 0 0 0 0 0
Tachysystole 0 0 0 0 0 0
Hyperstimulation 0 0 0 0 0 0
Fetal heart rate abnormalities 6 20 1 5 7 14
Meconium 
Passage
Thin 5 16.
6
0 0 5 10
Thick 1 3.3 0 0 1 2
None  of  the  study  population  had  uterine  contraction 
abnormalities.
A total of 14% that is 6 primi (20%) and 1(5%) multi had 
FHR abnormalities.
A total of 10%, that is 5 (16.6%) primi had thin meconium 
stained  liquor  and  1(3.3%)  primi  had  thick  meconium  stained 
liquor. But none of the multi had meconium stained liquor.
Table – 12
Mode of Delivery
Mode of Delivery PRIMI MULTI TOTAL TOTAL
No % No % No %
Labour 
Natural
24 80 20 100 44 88
Instrumental 
Delivery
Outlet 
forceps
5 16.7 0 0 5 10
Midcavity 
forceps
0 0 0 0 0 0
Vaccum 
delivery
0 0 0 0 0 0
LSCS Failed 
Induction
0 0 0 0 0 0
Fetal 
distress
1 3.3 0 0 1 2
30 100 20 100 50 100
Unassisted vaginal delivery ensued in a total of 88% that is in 
24 (80%) primi and 20 (100%) multigravida.
None of the multigravida required instrumental  delivery or 
underwent LSCS.
Only 5 primi (16.6%) required instrumental delivery (in the 
form of outlet forceps delivery) that is a total of 10%.
Only 1(3.3%) primi was taken up for LSCS for fetal distress, 
that is a total of 2%.
Table – 13
Maternal Complications
Complications PRIMI MULTI TOTAL TOTAL
No % No % No %
Nausea vomiting 2 6.7 1 5 3 6
Fever 4 13.3 0 0 4 8
Puerperal sepsis 0 0 0 0 0 0
Rupture uterus 0 0 0 0 0 0
Postpartum hemorrhage 0 0 0 0 0 0
Requirement  for  blood 
transfusion
0 0 0 0 0 0
The incidence of minor maternal complications in the form of 
nausea and vomiting were seen in a total of 6%, that is in 2 (6.7%) 
primi and  1 (5%) multigravida.  Fever was seen in a total of 4 (8%) 
that is in 4(13.3%) primi and none of the multigravida
Major maternal complications like post partum hemorrhage 
and requirement for blood transfusions, rupture uterus or puerperal 
sepsis were nil  in this series of 50 patients both in multi  and in 
primi gravida showing the safety and efficacy of the regime.
Table - 14
Neonatal Outcome
Parameters PRIMI MULTI TOTAL TOTAL
No % No % No %
Mean birth weight in kgs 2.9 2.81 2.86
5 min Apgar < 7 4 13.3 1 5 5 10
Meconium  Aspiration 
syndrome
1 3.3 Nil 0 1 2
Neonatal I.C.U. admission 6 20 1 5 7 14
Neonatal mortality 0 0 0 0 0 0
5 minute Apgar score less than 7 was seen in a total  of 5 
(10%) that is in 4 primi (13.3%) and 1(5%) multigravida
The incidence of meconium Aspiration syndrome was seen in 
a  total  of  1(2%)  that  is  in  1(3.3%)  primi  and  in  none  of  the 
multigravida.
A total of 7(14%) Newborn babies were required admission 
in NICU, that is 6 babies born to primi gravidas and 1(5%) baby 
born to multigravida.
All  admitted  newborn  babies  were  discharged  on  1st PND 
except  one  baby  who  developed  MAS  (HIE  I)  treated  and 
discharged on 5th PND.
Table 15
Outcome of Induction
Out come PRIMI MULTI TOTAL TOTAL
No % No % No %
Success 27 90 20 100 47 94
Failure 3 10 0 0 3 6
The success of induction was seen in 27 (90%) of the total 30 
primi and 20 multigravida that is a total of 47 (94%) of the study 
group.
Failed  induction  was  seen  in  3  (10.0)  of  the  total  30 
primigravida  and  in  none  of  the  multigravida,  that  is  a  total  of 
3(6%) of study group.
Of the 3 primigravida, 1 underwent lower segment cesarean 
section for fetal distress while 2 primigravida required PGE2 gel for 
induction of labour on Day 4, as their Bishop’s score were < 6.
DISCUSSION
50 cases admitted in Government Rajaji  Hospital,  Madurai 
for confinement were recruited for this study.
Inclusion Criteria :
The patients were induced in this study after they satisfied all 
the  inclusion  criteria.   In  this  aspect,  this  study  correlates  with 
Randomized  control  trial  conducted  by  Stenlund  et  al, 
Department of woman and child health, Karolinska Hospital, 
Stockholm, Sweden, Oct 1999.
Age :
In  this  study,  27  (90%)  primi  and  17  (25%)  multigravida 
were between the age group of 21-30 years.  This study correlates 
with  randomized  controlled  trial  conducted  by  Wing  et  al, 
Department  of  Obstetrics  and  Gynecology,  University  of 
Southern California, Los Angels, Oct 2000 in which 88% of the 
patients were in the age group of 21-30 years.
Gravidity :
Both primi (60%) and multigravida (40%) were included in 
the study.  In this aspect our study correlates with studies done by 
Giacalone  et  al,  Department  of  Obstetrics  and  Gynecology, 
Hospital Arnaud de villeneuve, University of Montepetlier, Oct 
1998.
Treatment Schedule :
In our study, 200 mg mifepristone was given orally on Day 1, 
Bishop’s  scores  were  assessed  after  24  hrs,  if  less  than  6  and 
reactive PHR pattern, 2nd dose of 200 mg mifepristone orally was 
given. If Bishop’s score remained less than 6 after 48 hrs, PGE2 gel 
induction was done on Day 4 (0.5mg intracervically) which was 
repeated 12 hours later if necessary.
In  this  aspect,  our  study  correlates  with  randomized 
controlled  study  done  by  Frydman  et  al,  Department  of 
Obstetrics  and  Gynecology,  Hospital  Antoine  Beclere, 
Clormart, France in which study population received 200 mg of 
mifepristone on day 1 and 2 of a 4 days observational period with 
labour induction using prostaglandin planned on Day 4. 
Bishop’s Score at the start of the study :
In our study, patients with Bishop’s score of less than 4 were 
included in the study group.  
In this aspect,  our study correlates with the study done by 
Elliot  et  al,  Department  of  obstetrics  and  Gynecology, 
University  of  Edinburh,  United  Kingdom in  which  modified 
Bishop score of 4 less were included in the study group.
Oxytocin Augmentation :
In our study, 5 (16.7%) Primi and none of the multi gravida, 
that is a total of 10% required oxytocin for augmentation.
In this aspect,  our study correlates with the study done by 
Frydmen et al in which patient who deliveries vaginally needed a 
much lower amount of oxytocin when mifepristone had been given.
Duration of First and Second stage of labour :
In this study, a total of 87.8% that is 23 (79.2%) primi and 20 
multi (100%) had a first stage duration of less than 12 hrs.  The 
mean duration of first stage in primi was 9.79 hrs and in multi was 
6.98 hours.
In this study, a total of 98% that is 28 (96.5%) primi and 20 
(100%)  multigravida  had  second  stage  duration  less  than  30 
minutes.  The mean duration of second stage in primi was 16.06 
minutes and in multi was 10.78 minutes.
The  mean  duration  of  first  and  second  stage  was  less  in 
multigravida.
These  results  are  consistent  with  the  normal  WHO 
standards.
Induction and Delivery Interval :
In this study, mean induction delivery interval was 18.41 hrs. 
The mean induction delivery interval in primi was 23.11hrs and in 
multi was 11.48 hrs.  
Parity influenced the likelihood of vaginal delivery within 48 
hours.
According to the randomized controlled trial conducted by 
Wing et al, mean induction delivery interval was 26.8 + 11 hours. 
87.5%  women  who  received  mifepristone  delivered  vaginally 
within  48  hrs.  In  our  study  96.3%.  Women  delivered  vaginally 
within 48 hrs.
Mode of delivery :
In our study, the incidence of spontaneous vaginal delivery 
was 88% that is in 24 (80%) primi and 20 (100%) multigravida.
In  our  study,  the  instrumental  delivery  rate  was  10% and 
LSCS rate was 4% which was not statistically significant and in 
this aspect our study is consistent with Wing DA et al study.
Intrapartum Complications :
In  our  study,  uterine  contractility  abnormalities  like 
hypertonus, hyperstimulation or tachysystole were not encountered 
with.  
This is in contrast  to study conducted by  Giacalone et al, 
Department  of  obstetrics  and  gynecology  University  of 
montpellier,  July 2001 in which mifepristone treated group had 
higher rates of hyperstimulation and tachysystole.
A total of 14%, that is 6 primi (20%) and 1(5%) multigravida 
had FHR abnormalities in our study. This is consistent with study 
conducted by Wing DA et al in which abnormal FHR pattern were 
found in 18.6% of the study group.
In our study, a total of 10%, that is 5 (16.6%) primi had thin 
meconium stained liquor and 1(3.3%) primi had thick meconium 
stained liquor. But none of the multi had meconium stained liquor. 
This is  consistent  with study conducted by Wing et  al  in which 
16.5% infants from mifepristone group had MSAF.
Maternal Complications :
In  our  study,  none  of  our  study  population  had  major 
complications  like  rupture  uterus,  chorioamnionitis,  puerperal 
sepsis, post partum hemorrhage.
A total of 6% study population had minor complications like 
vomiting and fever.
In this aspect our study consistent with the study conducted 
by Stenlund et al, Karolinska Hospital, Stockholm, Oct 1999.
Neonatal Outcome :
In our study, a total  of 7 (14%) new born babies required 
admission  in  NICU.   Of  the  7  babies  one  baby  had  meconium 
aspiration  syndrome  and   HIE  stage  I,  baby  was  treated  and 
discharged on V PND.  Remaining six babies were admitted for 
Birth asphyxia.  All  babies were recovered and discharged on II 
PND.
None of the babies had neonatal convulsions, icterus or sepsis 
and perinatal mortality was nil.
In this aspect, our study is consistent with study conducted by 
Wing DA et al,  in which no statistically significant difference in 
neonatal outcomes between mifepristone treated group and control 
(placebo) group.
Outcome of Induction :
In our study, none of the study population underwent LSCS 
for failed induction.
Only 1(2%) primi underwent LSCS for fetal distress out of 
50 patients,  2 (4%) primigravida had unfavourable.  Bishop’s score 
after 48hrs and required induction with PGE2 gel on Day 4.  A total 
of 93.6% delivered within 48 hrs.
In the study conducted by Wing et al, 87.6% of mifepristone 
treated group delivered within 48 hours.  There was no statistically 
significant increase in caesarean section rate.
SUMMARY
The efficacy of  oral  mifepristone  as  an  induction  agent  is 
assessed in our study.  50 patients admitted in Government Rajaji 
Hospital,  Madurai  for  safe  confinement,  who  needed  induction, 
were included for this study.  50 patients satisfying the inclusion 
criteria for induction of labour were given 200 mg of mifepristone 
on Day 1 and Day 2 of 4 days observational period.  After 24 hrs, 
Bishop’s scores were reassessed, if Bishop’s score were more than 
6,  augmentation with oxytocin was done.   If  the  Bishop’s  score 
were remained unfavourable after 48 hrs induction with PGE2 gel 
was done on Day 4, after ensuring the Reactive FHR pattern.  This 
study documents  the  success  of  induction,  details  of  parturition, 
maternal  complications,  and  neonatal  outcome  and  meticulously 
the details of the results analysed.  The following are the summary 
of this study.
1. Majority of the patients belonging to this study group were in 
the age group of 21-30 years (88%) only 12% belonged to the 
age group of 18-20 years.
2. Analysis with regards to the parity showed that 60% of the 
study group were primi gravida and 40% were multigravida.
3. With  regards  to  the  indications  for  induction,  post  dated 
pregnancy  formed  the  majority  (90%)  and  the  other 
indication was preeclampsia (10%).
4. Majority of the patients in our study had a Bishop’s score of 
0  to  2  (84%)  at  the  beginning  of  the  induction.   Critical 
analysis  among  primi  and  multigravida  showed  that  the 
distribution was almost equal (86.7% primi vs 80% multi).
5. Analysing  the  number  of  doses  of  mifepristone  needed  to 
produce  mature  cervices  (Bishop’s  score  >6)  or  delivery. 
With single dose a total of 80%, that is 70% primi and 95% 
multi  either  delivered  or  having  mature  cervices  (Bishop 
score > 6) showing that the drug mifepristone is a effective 
inducing agent.  Only 20%, that is 30% primi and 5% multi 
gravida needed second dose.
6. Anaysing the need for oxytocin augmentation. Only 16.7% of 
the primigravida required oxytocin for augmentation. None 
of  multigravida  required  oxytocin  for  augmentation  ; 
mifepristone reduces the need for oxytocin augmentation.
7. Analysing the requirement of PGE2 gel for cervical ripening 
on  Day  4,  only  2  primigravida  (6.6%)  had  unfavourable 
Bishop score (Bishop’s score < 6) after 48 hrs and required 
PGE2 gel induction on Day 4.  But none of the multigravida 
had  unfavourable  Bishop’s  score  at  the  end  of  48  hrs, 
showing  that  mifepristone  is  a  effective  cervical  ripening 
agent.
8. Analysis  of  duration  of  first  stage  of  labour  revealed  that 
87.8% patient had first stage duration of less than 12 hours 
and all of the patients delivered within 16 hours, showing that 
the  drug  shortens  the  first  stage  duration  of  labour  in  the 
majority  (87.8%).  On  critical  analysis,  79.2%  primi  and 
100% multigravida had first  stage duration of less than 12 
hours,  showing  that  parity  influenced  the  likelihood  of 
vaginal delivery.
9. The duration of  second stage was less  than 30 minutes in 
98%  of  patients.   On  critical  evaluation  almost  all 
multigravida  and  96.5%  primigravida  had  second  stage 
duration of less than 30 minutes.   The mean second stage 
duration in primi and multi gravida being 16.06 minute and 
10.78 minutes respectively.
10. With  regards  to  the  induction  delivery  interval  (after 
subtracting the failure cases) 91.5% patients delivered within 
36 hrs of induction. Only 4 primi (19.7%) but none of the 
multigravida delivered after 36 hrs of induction.  The mean 
induction  delivery  interval  was  18.61  hrs.   The  mean 
induction is delivery interval  in primi was 23.7 hrs and in 
multigravida  was  11.48  hrs.   Therefore  induction  delivery 
interval was shorter in multigravida (p=0.001).
11. Intrapartum complications :   None of the study population 
had uterine contractility abnormalities, though 14% patients 
showed  FHR  abnormalities,  and  10%  had  thin  meconium 
stained  liquor  2% had  thick  meconium stained  liquor,  the 
neonatal outcome was good.
12. Unassisted vaginal delivery occurred in 100% multigravida 
and 80% multigravida. Only 5 (16.6%) primigravida required 
instrumental  delivery  (outlet  forceps)  and  1(3.3%) 
primigravida  underwent  LSCS  for  foetal  distress  showing 
that the drug is very effective in minimizing the ceasarean 
section rates to a base minimum.
13. There  were  no  major  maternal  complications  like  rupture 
uterus, post partum hemorrhage, and puerperal sepsis both in 
the primi and multigravida showing that safety and efficacy 
of this regime.  Only 6% patients had minor complications 
like nausea, vomiting and fever.
14. Critical  evaluation  of  the  neonatal  outcome  in  our  study 
revealed no statistical difference in the mean birth weight of 
the baby born (mean birth was 2.9 kgs and 2.81kgs in multi 
gravida)   In  10% of  the  new borns,  the  5  minutes  Apgar 
scores  were  less  than  7/10,  all  4  babies  were  admitted  in 
NICU and  observed  for  12  hours  and  discharged  after  12 
hours.   Apart  from  these  babies,  two  newborns,  one  for 
VLBW  (B.Wt  –  1.8kg)  and  one  for  MAS  (meconium 
aspiration syndrome) were admitted in the NICU.  The new 
born who had MAS developed HIE-I and treated in NICU, 
recovered and discharged on Vth PND.  Neonatal mortality 
was NIL and none of the babies had septicemia.
15. The outcome of induction in this study reveals that the drug 
was successful  in 94% of  the  cases.   Only 2 primigravida 
required PGE2 gel induction on Day 4 and 1 primi gravida 
underwent LSCS for foetal distress showing that mifepristone 
is a safe and effective drug for preinduction cervical ripening 
at term in patients with unfavourable cervices.
CONCLUSION
Our study reveals that oral  mifepristone is a very safe and 
effective  drug  for  the  induction  of  labour.   It  has  an  added 
advantage  of  the  case  of  administration  (oral).   This  drug 
effectively reduces the need for augmentation of labour in almost 
three fourth of the patients and with overall success rate of 94%.
The drug shortens the duration of the labour with absolutely 
no major maternal complications and  with absolutely safe neonatal 
outcome. Compare to overall hospital standards, when the drug is 
used, lower segment caesarean rates were minimal thereby showing 
that mifepristone is a safe and orally effective agent for induction 
of labour at term in patients with unfavourable cervices, but more 
studies are needed.
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STRUCTURE OF MIFEPRISTONE
11 beta (p-(Dimethyl amino) Phenyl)-
17 beta hydroxy – 17 –(1-propyanyl) estra 4,9-dien-3-one
REACTIVE NST
MIFEPRISTONE TABLETS
ABBREVIATIONS
NICU NEONATAL INTENSIVE CARE UNIT
MSAF MECONIUM STAINED AMNIOTIC FLUID
MAS MECONIUM ASPIRATION SYNDROME
HIE HYPOXIC ISCHEMIC ENCEPHALOPATHY
NST NON STESS TEST
WKS WEEKS
MIN MINUTES
KGS KILOGRAMS
MG MILLI GRAMS
FHRAb FETAL HEART RATE ABNORMALITY
PROFORMA
MIFEPRISTONE (RU 486) IN INDUCTION OF LABOUR.
Name :
Age :
IP No :
Socio economic status :
Obstetric Code :
Booked /unbooked :
Last mestural period :
Expected date of delivery :
HISTORY:
PAST HISTORY:
H/o Diabetes / Hypertension / Congenital or Rheumatic 
     Heart Disease/ 
H/o Drug Intake like anti coagulants / H/o Tuberculosis (or) 
    chronic lung disease H/o epilepsy / H/o Steroid therapy. 
H/o Surgeries
PERSONNEL HISTORY:
H/o Smoking
MENSTRUAL HISTORY:
H/o Regular Cycles
MARITAL HISTORY : 
 Married since        Yrs.
H/o Consanguinity
OBSTETRIC HISTORY
GENERAL EXAMINATION
Height
Weight
Anemic / not
Afebrile / febrile
Pedel oedema present / absent
Pulse rate:  
Blood pressure
Cardio vascular system
Respiratory system:
Abdominal Examination
Vaginal Examination 
Bishop’s score (modified) at the time  of Induction. :
 BASIC INVESTIGATIONS
Hb%
Urine   alb
 Sugar
Deposits
Blood grouping Rh typing
Blood    sugar
  Urea
  Sr. creatinine
Obstetric Scan  & Biophysical Profile
INDICATION FOR INDUCTION:
DATE AND TIME OF MIFEPRISTONE (200 MG ORALLY) 
ADMINISTRATION
DOSE DATE TIME
IST Dose
IInd Dose
BISHOP SCORE AFTER 24HRS & 48 HOURS 
Bishop score after 24 hr After 48 hrs
Oxytoxin Augmentation : Needed / not
Dose and duration
Duration of first stage __________    in hours
Duration of second stage    ___________in minutes
Mode of delivery Labour natural / Instrumental delivery /LSCS
Induction delivery Interval:
Intra partum complications:
Maternal Complications:
Neonatal outcome:
Birth weight
Apgar   1’
5’
If admitted in NICU,  Outcome of the newborn.



